PepGen said early data from a small 12-week study in six patients with myotonic dystrophy type 1 (DM1) look “promising” on a key measure. The update is positioned as incremental evidence in a competitive field that recently saw a DM1 Phase 3 disappointment tied to a drug Novartis acquired. The report frames PepGen as a late entrant to DM1 therapeutics, where efficacy benchmarks increasingly depend on functional muscle control endpoints and durability signals. The company did not provide full Phase 2 or pivotal details in the excerpt, but the timing suggests an effort to re-accelerate interest as the field looks for compounds that meaningfully translate to clinical outcomes. For the market, the juxtaposition with recent setbacks highlights how quickly trial narratives can shift in neuromuscular development—and how early patient-level readouts still shape capital allocation ahead of larger studies.